

Please return completed form to acoates@thyroid.org or fax to 703-998-8893.

School of Medicine

Disclosure of Relevant Financial Relationships

Your role Planner Faculty Course Director Title of CME Activity. Presentation Title(s): Presentation Title(s	Name: Date	of Activity:	GLOSSARY
Tille of CMF Activity. Presentation Title(s): Presen	Your role: Planner		
Presentation Title(s): Presentation to the continue to the decides of the beginning of the presentation. Peer ACCME requirements, persons who fall to sign and return this form are not eligible to be involved with this activity: #1: Disclosure of Relevant Financial Relationship - List the names of proprietary entities producing health care goods/services, with the exemption of non-profit or government organizations and on-habit care relevant formatical relationship in the past 12 months. #1: Disclosure of Relevant Financial Relationships - List the names of proprietary entities producing health care goods/services, with the exemption of non-profit or government organizations and on-habit care relevant formatical relationship (skip to #2 below.) Yes, I do have a relevant financial relationship (skip to #2 below.) Yes, I do have a relevant financial relationship (skip to #2 below.) Speaker's Bureau Grant/Research Support Grant/Research Su	Title of CME Activity:		as any entity producing, marketing, re-selling,
Pre-Bauls in equalisation of the pre-bauls** in excender of this deer Probe procession. **Per ACCME requirements, persons who fall to sign and return this form are not eligible to be involved with this activity. **##**## Thisciosure of Relevant Financial Relationships — List the names of proprietary entities producing health care goods/services, with the exemption of non-profit or government organizations and non-health care related companies. with which you/your spouse/partner have, or have had, a relevant financial relationship exemption of non-profit or government organizations and non-health care related companies. with which you/your spouse/partner have, or have had, a relevant financial relationship. (Skip to #2 below) WITH RESPECT TO THIS SPECIFIC CME ACTIVITY (check one): No. 1 do not have a relevant financial relationship. (Skip to #2 below) Yes, I do have a relevant financial relationship. (Skip to #2 below) Speakers Bureau Granufkesearch Support Granu	• • • • • • • • • • • • • • • • • • • •	consumed by or used on patients. The	
Pre ACCME requirements, persons who fail to sign and return this form are not eligible to be involved with this activity. ### Disclosure of Relevant Financial Relationships — Let the names of proprising verifies producing health care good/senvices, with the exemption of non-profit or government organizations and non-bath care relevant financial relationship. (Skip to #2 below.) WITH RESPECT TO THIS SPECIFIC CME ACTIVITY (check one): No, I do not have a relevant financial relationship. (Skip to #2 below.) Ves., I do have a relevant financial relationship. (Skip to #2 below.) Ves., I do have a relevant financial relationship. (Skip to #2 below.) Speaker's Bureau		service directly to patients to be commercial	
##1: Disclosure of Relevant Financial Relationships - List the names of proprietary entities producing health care goods/services, with the exemption of non-profit or government organizations and non-health care related companies, with which you/your spouse/partner have, or have had, a relevant financial relationship within the past 12 months. WITH RESPECT TO THIS SPECIFIC CME ACTIVITY (check one):		for ACCME accreditation. Financial Relationship	
No, 1 do not have a relevant financial relationship. Provide information below: Nature of Relevant Financial Relationship (choose all that apply) Name of Company(s)	List the names of proprietary entities producing health care goods, organizations and non-health care related companies, with which financial relationship within the past 12 months.	in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as	
Nature of Relevant Financial Relationship (choose all that apply) Speaker's Bureau Grant/Research Support Consultant Stock Shareholder (directly purchased) Honoraria Honoraria Grant/Research Support Honoraria Honoraria		independent contractor (including contracted	
Consultant Speaker's Bureau			membership on advisory committees or
Speaker's Bureau	•	Name of Company(s)	activities from which remuneration is received,
Grant/Research Support Grant/	Speaker's Bureau		of the person involved in the CME activity to
Consultant	Grant/Research Support		spouse/partner.
□ Stock Shareholder (directly purchased) □ Honoraria □ Full-time/part-time Employee □ Other (explain): #2: Disclosure of Off-Label and/or Investigational Uses − If, at any time, during my education activity I discuss an off-label/investigative (unapproved) use of a commercial product/device, understand that I must provide disclosure of that intent. □ No, I do not intend to discuss and fi-label/investigative uses of a commercial product/device, (Skip to #3 below.) □ Yes, I do intend to discuss and fi-label/investigative uses of a commercial product(s)/device(s): #3: Presentation(s) Content: Faculty Responsibility − • The Presenter warrants that nothing in their presentation is libelous or will infringe the rights of any third party. Presenter also warrants that for any third party materials incorporated into their presentation, there of the angular variables of the use of such materials. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter is responsible for all damages, costs and expenses, including attorneys' fees, incurred by OCME &PD as a result of a violation of this paragraph. • CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational material or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company.	Consultant		ACCME focuses on financial relationships with
Honoraria the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines "relevant financial relationships as financial relationships has calculated the relationship. The ACCME defines "relevant financial relationships in any amount occurring within the past 12 months that create a conflict of interest and that I must provide disclosure of that intent. No, I do not intend to discuss an off-label/investigative uses of a commercial product/device. (Skip to #3 below.) Yes, I do intend to discuss off-label/investigative uses(s) of the following commercial product(s)/device(s): *3: Presentation(s) Content: Faculty Responsibility − • The Presenter warrants that nothing in their presentation is libelous or will infringe the rights of any third party. Presenter also warrants that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such material. Upon request Presenter agrees to furnish copies of said permission(s) to OCME &PD. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter shall indemnify OCME & PD for all damages, costs and expenses, including attorneys' fees, incurred by OCME &PD as a result of a violation of this paragraph. • CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational material or content includes trade names from a single company. by checking this box, I attest that the completed information is accurate. Please accept this as my signature.	Stock Shareholder (directly purchased)		preceding the time that the individual is being
□ Other (explain): #2: Disclosure of Off-Label and/or Investigational Uses − If, at any time, during my education activity! discuss an off-label/investigative (unapproved) use of a commercial product/device, I understand that I must provide disclosure of that intent. No, I do not intend to discuss an off-label/investigative use of a commercial product/device. (Skip to #3 below.) Yes, I do intend to discuss off-label/investigative uses(s) of the following commercial product(s)/device(s): #3: Presentation(s) Content: Faculty Responsibility − • The Presenter warrants that nothing in their presentation is libelous or will infringe the rights of any third party. Presenter also warrants that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such material. Upon request Presenter agrees to furnish copies of said permission(s) to OCME &PD. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter is responsible for all fees, royalties, and other charges including attorneys' fees, incurred by OCME &PD as a result of a violation of this paragraph. • CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational material or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company.	Honoraria		the CME activity. ACCME has not set a
Other (explain):	Full-time/part-time Employee		significant. Inherent in any amount is the
#2: Disclosure of Off-Label and/or Investigational Uses – If, at any time, during my education activity I discuss an off-label/investigative (unapproved) use of a commercial product/device, I understand that I must provide disclosure of that intent. No, I do not intend to discuss an off-label/investigative use of a commercial product/device. (Skip to #3 below.) Yes, I do intend to discuss off-label/investigative uses(s) of the following commercial product(s)/device(s): #3: Presentation(s) Content: Faculty Responsibility – • The Presenter warrants that nothing in their presentation is libelous or will infringe the rights of any third party. Presenter also warrants that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such material. Upon request Presenter agrees to furnish copies of said permission(s) to OCME &PD. The Presenter is responsible for all fees, royalties, and other charges including attorneys' fees, incurred by OCME &PD as a result of a violation of this paragraph. • CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational material or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company. ### Disclosure of Mt. Each Use and/or Investigational Uses FDA Statement **Off-Label Use and/or Investigative disclosure form, it is your responsibility to inform OCME &PD or have been deared by the FDA or have been cleared by the FDA has stated that it is the responsibility of the physician to	Other (explain):		the relationship. The ACCME defines
#3: Presentation(s) Content: Faculty Responsibility – • The Presenter warrants that nothing in their presentation is libelous or will infringe the rights of any third party. Presenter also warrants that for any third party materials incorporated into their presentation, they have obtained all necessary permission from the copyright owner of such material. Upon request Presenter agrees to furnish copies of said permission(s) to OCME &PD. The Presenter is responsible for all fees, royalties, and other charges for the use of such materials. The Presenter shall indemnify OCME & PD for all damages, costs and expenses, including attorneys' fees, incurred by OCME &PD as a result of a violation of this paragraph. • CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational material or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company. By checking this box, I attest that the completed information is accurate. Please accept this as my signature.	If, at any time, during my education activity I discuss an off-label/ir I understand that I must provide disclosure of that intent. No, I do not intend to discuss an off-label/investigative	relationships in any amount occurring within the past 12 months that create a conflict of interest. After you submit the completed disclosure form, it is your responsibility to inform OCME &PD if the status of your financial relationship changes prior to your	
 CME must give a balanced view of therapeutic options. Use of generic drug names contributes to impartiality. Also, if your CME educational material or content includes trade names then trade names from several companies should be used where available, not just trade names from a single company. By checking this box, I attest that the completed information is accurate. Please accept this as my signature. 	#3: Presentation(s) Content: Faculty Responsibility – • The Presenter warrants that nothing in their presentation Presenter also warrants that for any third party materials all necessary permission from the copyright owner of stropies of said permission(s) to OCME &PD. The Presenter for the use of such materials. The Presenter shall indem	FDA Statement Some drugs or medical devices demonstrated have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical	
9/2010	CME must give a balanced view of therapeutic options. Use if your CME educational material or content includes to should be used where available, not just trade names from By checking this box, I attest that the completed inform	may be described in CME activities so long as the "off label" use of the drug or medical device is also specifically disclosed (i.e. it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used "off label" if the described use is not set forth on the product's approval label.	
	i filited Ivalite.		9/2018